$800 Per Month vs. $40 Per Month: The Hair Loss Medication Math That Nobody’s Talking About

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

According to hair restoration surgeon Dr. Gary Linkov, the answer may not be as straightforward as pharmaceutical companies would have you believe.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

According to hair restoration surgeon Dr. Gary Linkov, the answer may not be as straightforward as pharmaceutical companies would have you believe.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

But do those impressive-sounding statistics actually translate to noticeable cosmetic results?

According to hair restoration surgeon Dr. Gary Linkov, the answer may not be as straightforward as pharmaceutical companies would have you believe.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

But do those impressive-sounding statistics actually translate to noticeable cosmetic results?

According to hair restoration surgeon Dr. Gary Linkov, the answer may not be as straightforward as pharmaceutical companies would have you believe.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

A new topical hair loss treatment called clascoterone is making waves with headlines touting improvements of hundreds of percent in hair count.

But do those impressive-sounding statistics actually translate to noticeable cosmetic results?

According to hair restoration surgeon Dr. Gary Linkov, the answer may not be as straightforward as pharmaceutical companies would have you believe.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

A new topical hair loss treatment called clascoterone is making waves with headlines touting improvements of hundreds of percent in hair count.

But do those impressive-sounding statistics actually translate to noticeable cosmetic results?

According to hair restoration surgeon Dr. Gary Linkov, the answer may not be as straightforward as pharmaceutical companies would have you believe.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.

A new topical hair loss treatment called clascoterone is making waves with headlines touting improvements of hundreds of percent in hair count.

But do those impressive-sounding statistics actually translate to noticeable cosmetic results?

According to hair restoration surgeon Dr. Gary Linkov, the answer may not be as straightforward as pharmaceutical companies would have you believe.

In his recent analysis, Dr. Linkov examines clascoterone not through marketing language, but through mechanism of action, trial design, and real-world visible change—and raises important questions about whether we’re even measuring this drug the right way.

Understanding Androgenetic Alopecia and Current Treatments

Androgenetic alopecia represents the most common form of hair loss in both men and women. This hormone-driven condition involves dihydrotestosterone (DHT) causing progressive miniaturization of hair follicles.

Current prevention strategies focus on reducing DHT levels. Finasteride, for example, blocks conversion of testosterone to DHT systemically—but comes with potential side effects that concern many patients.

One of the main issues with finasteride is the potential for systemic side effects,

Dr. Linkov explains, pointing to the need for safer alternatives.

How Clascoterone Works Differently

Clascoterone operates through a fundamentally different mechanism than finasteride. Rather than reducing DHT production systemically, this topically applied medication works as an androgen receptor inhibitor directly at the scalp level.

The molecule competes with DHT for binding to androgen receptors—and actually has higher affinity for those receptors than DHT itself. Even with abundant circulating DHT, the hormone cannot bind effectively when clascoterone occupies the receptor sites.

This is what we call a competitive antagonist,

Dr. Linkov notes, highlighting that clascoterone was already approved for acne treatment under the name Winlevi back in 2020.

The Theoretical Safety Advantage

One major advantage: clascoterone rapidly metabolizes to an inactive form called cortexolone. This theoretically minimizes risk of systemic anti-androgenic side effects—potentially reducing need for oral anti-androgen medications.

The Phase 3 Trial Results: Impressive Numbers, But What Do They Mean?

In 2025, Cosmo Pharmaceuticals revealed Phase 3 results for clascoterone 5% solution showing significant hair growth improvement in androgenetic alopecia. Two large trials called SCALP-1 and SCALP-2 enrolled 1,465 men across the United States and Europe.

According to press releases, one trial showed a 5.39-fold (539%) relative improvement in target area hair count. The second demonstrated a 1.68-fold (168%) relative improvement compared to vehicle (placebo).

These numbers sound extraordinary—but Dr. Linkov warns they may be misleading.

The Problem With Relative Improvements

A relative improvement percentage of medication versus vehicle can definitely sound very impressive, especially when they say things like 540% more. That sounds like a huge number, but that could hide very small absolute differences,

Dr. Linkov explains.

For example, if clascoterone increased hair count by 7 hairs per square centimeter compared to 1.1 hairs in the placebo group, that’s an absolute difference of just 5.9 hairs per square centimeter—despite representing a 539% relative improvement.

That small absolute gain is unlikely to create visible cosmetic change.

• Relative improvements can inflate perceived efficacy
• Absolute clinical effect determines actual visible results
• Six additional hairs per square centimeter may not be noticeable

Examining the Photographic Evidence

Dr. Linkov analyzed before-and-after images released by Cosmo Pharmaceuticals alongside their press announcements. His assessment raises concerns about interpretation.

In the first example, he notes significant lighting differences between images. The before photo shows brighter flash creating darker perimeter areas and lighter central portions.

When you remove that heavy flash in the after images taken at 6 months post the use of clascoterone, you see that the overall central portion looks a little bit darker. While it could be the result of the medication, it could also be related to the changing of lighting,

he observes.

The second outcome photo shows similar flash effects without tremendous transformation. Even accounting for potential medication effects, results don’t appear as impressive as outcomes Dr. Linkov routinely sees with finasteride and minoxidil.

Comparison to Proven Treatments

Dr. Linkov shares a striking patient case: a man who received hair transplant only to his frontal scalp but experienced dramatic crown improvement through minoxidil and finasteride alone.

When he came back about a year after his surgery, we were shocked by how much improvement there was in his crown. I did not operate on his crown,

Dr. Linkov recalls, emphasizing how powerful established treatments truly are.

Based on published images, clascoterone doesn’t appear to offer equivalent—let alone superior—benefits compared to finasteride and minoxidil.

Early Phase Studies Show Mixed Results

Phase 1 and Phase 2 trials preceding the Phase 3 studies revealed important safety concerns and questionable efficacy data.

In Phase 1 trials with 18 patients, 72% experienced at least one treatment-emergent adverse event—though all were considered mild to moderate and resolved within 28 days. These primarily consisted of local skin reactions: erythema, scaling, and dryness.

The likely culprit? Propylene glycol—the same chemical in topical minoxidil solution that causes similar reactions in some users.

Phase 2 Statistical Concerns

Phase 2 results showed clascoterone outperforming other anti-androgens with favorable scalp hair growth at 39% versus 36% for minoxidil and 16% for vehicle.

However, these differences failed to reach statistical significance. The p-value was 0.2213—far above the standard 0.05 threshold required for most studies.

Dr. Linkov also notes potential bias: Cosmo Pharmaceuticals conducted this research themselves and published only an abstract rather than a full article.

The Cost Factor: Is It Worth It?

Even if clascoterone (marketed as Breezula if approved) proves effective, accessibility remains questionable.

Insurance companies typically don’t cover hair loss treatments, making this an out-of-pocket expense. Based on the cost of Winlevi (the acne formulation), patients could face $600-$800 per 60-gram tube.

Treating DHT-sensitive zones requires approximately 1.5-3 grams of product, providing roughly 30 applications per tube—essentially one month of treatment.

• Clascoterone potential cost: $800 per month
• Topical finasteride cost: approximately $40 per month
• Cost difference: 20 times more expensive

So even if Breezula is approved, I think it’s important to run it against some other topical medications for hair loss to see which is actually more effective before people have to spend 20 times the amount on the newer medication,

Dr. Linkov cautions.

Are We Judging Clascoterone Through the Wrong Lens?

Dr. Linkov suggests we may be evaluating clascoterone incorrectly by comparing it to growth-stimulating treatments.

Recent medications like PP405 and monounsaturated fatty acids work by stimulating hair follicle stem cells—a fundamentally different mechanism than blocking DHT effects. Clascoterone more closely resembles finasteride and dutasteride in preventing hair loss rather than dramatically boosting hair counts.

Clascoterone is being judged through a growth lens when it may just be more of a maintenance drug,

he notes.

Defense Over Offense

Dr. Linkov emphasizes that effective hair loss management focuses primarily on long-term follicle protection rather than dramatic regrowth.

Finasteride, for instance, sometimes grows new hair—but its main benefit lies in preventing further loss. That same “defense first” philosophy should apply to evaluating clascoterone.

The real test will be whether patients with androgenetic alopecia can maintain existing hair using topical clascoterone while avoiding systemic side effects of oral anti-androgen medications.

The Bottom Line on Clascoterone

Clascoterone represents an interesting addition to hair loss treatment options with a novel topical mechanism that theoretically minimizes systemic side effects.

However, several concerns temper enthusiasm:

• Statistical reporting emphasizes relative rather than absolute improvements
• Photographic evidence shows modest results potentially confounded by lighting differences
• Cost considerations make it significantly more expensive than proven alternatives
• Limited published data from company-sponsored research raises transparency questions
• Mechanism suggests maintenance rather than dramatic regrowth

New doesn’t always mean better. As Cosmo Pharmaceuticals completes 12-month safety follow-up and pursues FDA approval, independent head-to-head comparisons with established topical treatments will be essential.

Until then, patients should view clascoterone as a potentially useful maintenance option—not a revolutionary breakthrough—and carefully weigh costs against proven, affordable alternatives like topical finasteride and minoxidil.